Loading
A phase 2 trial of Ibritumomab tiuxetan and Rituximab in Non-Hodgkin lymphoma, run by University of Wisconsin, Madison, recorded as terminated on the registry.
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance is a phase 2 interventional study registered as NCT00582166 by University of Wisconsin, Madison, with 18 participants recorded, started 2005-01-25 and due to reach its primary completion in 2013-03. Interventions recorded: Ibritumomab Tiuxetan (Zevalin) + Rituximab. Conditions recorded: Non-Hodgkin's Lymphoma.
Linked to the drug Ibritumomab tiuxetan because the registry names it among its interventions and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
18 enrolled.
80% CI 32.8 to 46.1; Figures from the ClinicalTrials.gov results section (first posted 2018-07-13), not from a publication
Source95% CI 80 to 100; Figures from the ClinicalTrials.gov results section (first posted 2018-07-13), not from a publication
SourceThe full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ibritumomab tiuxetan, Rituximab and the tag pipeline.
Shares Ibritumomab tiuxetan and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/